{"id":"W4297981965","doi":"10.1016/j.annonc.2022.08.052","title":"LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi Genzyme; European Society for Medical Oncology; F. Hoffmann-La Roche; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Internal medicine; Regimen; Gemcitabine; Taxane; Oncology; Clinical endpoint; Vinorelbine; Chemotherapy regimen; Phases of clinical research; Chemotherapy; Cancer; Clinical trial; Cisplatin; Breast cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002376703,0.001611018,0.003014611,0.0005116264,0.0004758658,0.00160839,0.001336547,0.001694298,0.004519511],"category_scores_gemma":[0.001439341,0.0006934845,0.00250016,0.0005410296,0.001344891,0.001493116,0.0004568632,0.005829439,0.0013044],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00109884,"about_ca_system_score_gemma":0.001788829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001168953,"about_ca_topic_score_gemma":0.003674533,"domain_scores_codex":[0.9993665,0.000293662,0.00003083331,0.0001202243,0.0000511755,0.0001376289],"domain_scores_gemma":[0.9987687,0.0003290185,0.0002159804,0.0001046164,0.00005436594,0.0005271974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8462915,0.0434241,0.007173411,0.0006392588,0.001823708,0.0001202213,0.0001780899,0.001977402,0.01835228,0.0002629946,0.004191492,0.07556562],"study_design_scores_gemma":[0.5720139,0.3978714,0.0214376,0.00005448208,0.001718125,0.0002728665,0.00008899441,0.001059581,0.002606829,0.0002597044,0.002564341,0.00005229935],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896901,0.002805829,0.0003968069,0.0008464802,0.0002622736,0.001002549,0.002791616,0.0001269187,0.002077466],"genre_scores_gemma":[0.9833354,0.002746468,0.001207202,0.001412594,0.000393429,0.001202377,0.006609546,0.00007425463,0.003018728],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004519511,"threshold_uncertainty_score":0.01511931,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08437136665025254,"score_gpt":0.3660597961296059,"score_spread":0.2816884294793534,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}